Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Warts 1

Interventions

Cryotherapy 12resiquimod 6Cantharidin 5PRA1 protein, Candida albicans 4Tuberculin 3Salicylic Acid 3Cholecalciferol 3plerixafor 2VP-102 2Solutions 2Sodium Chloride 2Saline Solution 2Photochemotherapy 2Percutaneous Collagen Induction 2N-phenylacetoaminomethylene-DL-p-nitrophenylalanine 2Measles-Mumps-Rubella Vaccine 2Lasers 2Hydrogen Peroxide 2Human Papillomavirus Recombinant Vaccine nonavalent 23-ingenyl angelate 22-Propanol 2methyl 5-aminolevulinate 1leupin 1lactic acid, salicylic acid drug combination 1human papillomavirus vaccine, L1 type 16, 18 1green tea extract polyphenone E 1gluconic acid 1ethyl pyruvate 1compound W 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Warts × Nitric Oxide × Clear all
NCT05877313 2024-04-17

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)

Sanotize Research and Development corp.

Phase 2 Completed
20 enrolled

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡